MediciNova Inc
MNOV1.370USD
-0.060-4.20%
Market hours （ET）Quotes delayed by 15 min
67.19MMarket Cap
LossP/E TTM
More Details of MediciNova Inc Company
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Company Info
Ticker SymbolMNOV
Company nameMediciNova Inc
IPO dateDec 01, 2006
CEODr. Yuichi Iwaki, M.D., Ph.D.
Number of employees13
Security typeOrdinary Share
Fiscal year-endDec 01
Address4275 Executive Square
CityLA JOLLA
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code92037
Phone18583731500
Websitehttps://medicinova.com/
Ticker SymbolMNOV
IPO dateDec 01, 2006
CEODr. Yuichi Iwaki, M.D., Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Mr. Jason J. Kruger
Mr. Jason J. Kruger
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Yuichi Iwaki, M.D., Ph.D.
Dr. Yuichi Iwaki, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.09M
--
Dr. Kazuko Matsuda, M.D., Ph.D.
Dr. Kazuko Matsuda, M.D., Ph.D.
Chief Medical Officer, Director
Chief Medical Officer, Director
323.00K
--
Dr. David H. Crean, Ph.D.
Dr. David H. Crean, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Ms. Carolyn D. Beaver
Ms. Carolyn D. Beaver
Independent Director
Independent Director
--
--
Ms. Nicole Lemerond
Ms. Nicole Lemerond
Independent Director
Independent Director
--
--
Mr. Hideki Nagao
Mr. Hideki Nagao
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Feb 23
Updated: Sun, Feb 23
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Shareholders
Shareholders
Proportion
3D Investment Partners Pte. Ltd
11.22%
EW Healthcare Partners
2.25%
Iwaki (Yuichi)
2.23%
BlackRock Institutional Trust Company, N.A.
1.41%
The Vanguard Group, Inc.
1.27%
Other
81.62%
Shareholder Types
Shareholders
Proportion
Investment Advisor
14.01%
Investment Advisor/Hedge Fund
3.34%
Individual Investor
2.98%
Venture Capital
2.25%
Research Firm
1.79%
Hedge Fund
0.47%
Bank and Trust
0.02%
Other
75.13%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
68
12.20M
24.87%
-484.88K
2025Q1
73
12.20M
24.88%
-318.34K
2024Q4
74
12.23M
24.94%
+65.83K
2024Q3
73
11.92M
24.31%
+15.81K
2024Q2
76
11.78M
24.02%
-90.59K
2024Q1
75
11.47M
23.39%
-882.87K
2023Q4
77
11.84M
24.14%
-895.64K
2023Q3
90
12.02M
24.50%
-1.28M
2023Q2
106
12.39M
25.26%
-1.32M
2023Q1
131
12.60M
25.68%
-2.90M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
3D Investment Partners Pte. Ltd
5.50M
11.22%
--
--
Apr 21, 2025
EW Healthcare Partners
1.11M
2.25%
--
--
Mar 31, 2025
Iwaki (Yuichi)
1.09M
2.23%
--
--
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
691.21K
1.41%
-1.45K
-0.21%
Mar 31, 2025
The Vanguard Group, Inc.
623.57K
1.27%
+241.00
+0.04%
Mar 31, 2025
Citi Investment Research (US)
591.96K
1.21%
+90.00K
+17.93%
Mar 31, 2025
Geode Capital Management, L.L.C.
527.00K
1.07%
+12.09K
+2.35%
Mar 31, 2025
Matsuda (Kazuko)
323.00K
0.66%
--
--
Apr 21, 2025
Susquehanna International Group, LLP
250.12K
0.51%
-1.26K
-0.50%
Mar 31, 2025
UBS Financial Services, Inc.
222.20K
0.45%
-538.00
-0.24%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dimensional US Core Equity 1 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
